Christine Solbach

Mammography: density equalizing mapping of the global research architecture.

Dörthe Brüggmann, Matthias Grimstein, Christine Solbach, 2021, Quantitative imaging in medicine and surgery.

Identification of high risk breast-cancer patients by gene expression profiling

Christine Solbach, T. Karn, A. Ahr, 2002, The Lancet.

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Peter A. Fasching, Carsten Denkert, Mahdi Rezai, 2016, Clinical Cancer Research.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

Achim Rody, Christine Solbach, Dirk Metzler, 2009, Breast Cancer Research.

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

Tanja Fehm, Carsten Denkert, Peter A Fasching, 2012, The New England journal of medicine.

HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma

Stefan Joos, Peter Lichter, Christine Solbach, 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

A clinically relevant gene signature in triple negative and basal-like breast cancer

Lajos Pusztai, Achim Rody, Marcus Schmidt, 2010, Breast Cancer Research.

Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures

Lajos Pusztai, Eugen Ruckhäberle, Achim Rody, 2011, PloS one.

Value of Electrical Impedance Scanning (EIS) in the Evaluation of BI-RADS™ III/IV/V-Lesions

Christine Solbach, B. Scholz, T. Vogl, 2005, Technology in cancer research & treatment.

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Carsten Denkert, Christine Solbach, K. Dietrich, 2012, Breast Cancer Research and Treatment.

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Carsten Denkert, Jan Budczies, Wilko Weichert, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Kevin R Coombes, Lajos Pusztai, Eugen Ruckhäberle, 2012, European journal of cancer.